A pharmacoeconomic evaluation of pharmaceutical treatment options for prostate cancer

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Zaorsky NG, Lin J, Ba D, et al. The cost of prostate cancer care to society and to patients in the United States. J clin oncol. 2019;37(7_suppl):116. 03/01 2019. .
   Web of Science ®Google Scholar
• Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011 Nov;65(11):1180–1192.
   PubMed Web of Science ®Google Scholar
• Tannock IF, De Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004 Oct 7;351(15):1502–1512. .
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004 Oct 7;351(15):1513–1520.
   PubMed Web of Science ®Google Scholar
• Dellis A, Papatsoris AG. Denosumab as a promising novel bone-targeted agent in castration resistant prostate cancer. Expert Opin Biol Ther. 2014;14(1):7–10. 01/01 2014. .
   PubMed Web of Science ®Google Scholar
• Dellis A, Papatsoris AG. The economics of abiraterone acetate for castration-resistant prostate cancer. Expert Rev Pharmacoecon Outcomes Res. 2014 Apr;14(2):175–179.
   PubMed Web of Science ®Google Scholar
• Mottet N, Van Den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2021 Feb;79(2):243–262. .
   PubMed Web of Science ®Google Scholar
• Cornford P, Van Den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol. 2021 Feb;79(2):263–282. .
   PubMed Web of Science ®Google Scholar
• Zeliadt SB, Penson DF. Pharmacoeconomics of available treatment options for metastatic prostate cancer. PharmacoEconomics. 2007;25(4):309–327.
   PubMed Web of Science ®Google Scholar
• Norum J, Nieder C. Treatments for Metastatic Prostate Cancer (mPC): a Review of Costing Evidence. PharmacoEconomics. 2017 Dec;35(12):1223–1236.
   PubMed Web of Science ®Google Scholar
• Huggins C, Hodges CV. Studies on prostatic cancer: i. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol. 2002 Jul;168(1):9–12.
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Witjes WP, Bjerklund-Johansen TE, et al. Therapies used in prostate cancer patients by European urologists: data on indication with a focus on expectations, perceived barriers and guideline compliance related to the use of bisphosphonates. Urol Int. 2012;89(1):30–38.
   PubMed Web of Science ®Google Scholar
• Dellis A, Zagouri F, Liontos M, et al. Management of advanced prostate cancer: a systematic review of existing guidelines and recommendations. Cancer Treat Rev. 2019 Feb;73:54–61.
   PubMed Web of Science ®Google Scholar
• Sharifi N, Dahut WL, Steinberg SM, et al. A retrospective study of the time to clinical endpoints for advanced prostate cancer. BJU Int. 2005 Nov;96(7):985–989. .
   PubMed Web of Science ®Google Scholar
• Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015 Aug 20;373(8):737–746.
   PubMed Web of Science ®Google Scholar
• James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016 Mar 19;387(10024):1163–1177.
   PubMed Web of Science ®Google Scholar
• Vale CL, Burdett S, Rydzewska LHM, et al. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncol. 2016 Feb;17(2):243–256. .
   PubMed Web of Science ®Google Scholar
• Morgans AK, Chen YH, Sweeney CJ, et al. Quality of Life During Treatment With Chemohormonal Therapy: analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer. J Clin Oncol. 2018 Apr 10;36(11):1088–1095.
   PubMed Web of Science ®Google Scholar
• James ND, De Bono JS, Spears MR, et al. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. N Engl J Med. 2017;377(4):338–351. .
   PubMed Web of Science ®Google Scholar
• Fizazi K, Tran N, Fein L, et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2017 Jul 27;377(4):352–360. .
   PubMed Web of Science ®Google Scholar
• So A, Chin J, Fleshner N, et al. Management of skeletal-related events in patients with advanced prostate cancer and bone metastases: incorporating new agents into clinical practice. Can Urol Assoc J. 2012;6(6):465–470.
   PubMed Web of Science ®Google Scholar
• Barqawi YK, Borrego ME, Roberts MH, et al. Cost-effectiveness model of abiraterone plus prednisone, cabazitaxel plus prednisone and enzalutamide for visceral metastatic castration resistant prostate cancer therapy after docetaxel therapy resistance. J Med Econ. 2019 Nov;22(11):1202–1209.
   PubMed Web of Science ®Google Scholar
• Gillessen S, Attard G, Beer TM, et al. Management of Patients with Advanced Prostate Cancer: the Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. 2018 Feb;73(2):178–211. .
   PubMed Web of Science ®Google Scholar
• Heidegger I, Brandt MP, Heck MM. Treatment of non-metastatic castration resistant prostate cancer in 2020: what is the best? J Urol Oncol. 2020;38(4):129–136. 04/01/2020. .
   PubMed Web of Science ®Google Scholar
• Saad F. Evidence for the efficacy of enzalutamide in postchemotherapy metastatic castrate-resistant prostate cancer. Ther Adv Urol. 2013;5(4):201–210.
   PubMedGoogle Scholar
• Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014 Jul 31;371(5):424–433. .
   PubMed Web of Science ®Google Scholar
• Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012 Sep 27;367(13):1187–1197. .
   PubMed Web of Science ®Google Scholar
• Hussain M, Fizazi K, Saad F, et al. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2018 Jun 28;378(26):2465–2474. .
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Fizazi K, Saad F, et al. Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2020 Jun 4;382(23):2197–2206.
   PubMed Web of Science ®Google Scholar
• Smith MR, Saad F, Chowdhury S, et al. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. N Engl J Med. 2018 Apr 12;378(15):1408–1418.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Shore N, Tammela TL, et al. Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2019 Mar 28;380(13):1235–1246.
   PubMed Web of Science ®Google Scholar
• De Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010 Oct 2;376(9747):1147–1154. .
   PubMed Web of Science ®Google Scholar
• Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011 Mar 5;377(9768):813–822.
   PubMed Web of Science ®Google Scholar
• Parker C, Nilsson S, Heinrich D, et al. Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer. N Engl J Med. 2013;369(3):213–223. .
   PubMed Web of Science ®Google Scholar
• Aguiar PN Jr., Tan PS, Simko S. Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer. Einstein. 2019 Mar 7;17(2):eGS4414.
   PubMed Web of Science ®Google Scholar
• Chiang CL, So TH, Lam TC, et al. Cost-effectiveness analysis of Abiraterone Acetate versus Docetaxel in the management of metastatic castration-sensitive prostate cancer: hong Kong’s perspective. Prostate Cancer Prostatic Dis. 2020 Mar;23(1):108–115.
   PubMed Web of Science ®Google Scholar
• Ramamurthy C, Handorf EA, Correa AF, et al. Cost-effectiveness of abiraterone versus docetaxel in the treatment of metastatic hormone naïve prostate cancer. Urol Oncol. 2019 Oct;37(10):688–695.
   PubMed Web of Science ®Google Scholar
• Sathianathen NJ, Alarid-Escudero F, Kuntz KM, et al. A Cost-effectiveness Analysis of Systemic Therapy for Metastatic Hormone-sensitive Prostate Cancer. European Urology Oncology. 2019 Nov;2(6):649–655. .
   PubMed Web of Science ®Google Scholar
• Hu X, Qu S, Yao X, et al. Abiraterone acetate and docetaxel with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer in China: an indirect treatment comparison and cost analysis. Cost Effectiveness and Resource Allocation: C/E. 2019;17(1):27.
   PubMed Web of Science ®Google Scholar
• Beca J, Majeed H, Chan KKW, et al. Cost-effectiveness of docetaxel in high-volume hormone-sensitive metastatic prostate cancer. Can Urol Assoc J. 2019 Apr 26;13(12):396–403.
   PubMed Web of Science ®Google Scholar
• Zheng HR, Wen F, Wu YF, et al. Cost-effectiveness analysis of additional docetaxel for metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy from a Chinese perspective. Eur J Cancer Care (Engl). 2017 Nov;26(6):e12505.
   Web of Science ®Google Scholar
• Crawford ED, Shore N, Miller K, et al. Degarelix versus LHRH agonists: differential skeletal and urinary tract outcomes from an analysis of six comparative randomized clinical trials. J clin oncol. 2013;31(6_suppl):68. 02/20 2013.
   Web of Science ®Google Scholar
• Lee D, Porter J, Gladwell D, et al. A cost-utility analysis of degarelix in the treatment of advanced hormone-dependent prostate cancer in the United Kingdom. J Med Econ. 2014 Apr;17(4):233–247.
   PubMedGoogle Scholar
• Zhang P, Wen F, Fu P, et al. Addition of docetaxel and/or zoledronic acid to standard of care for hormone-naive prostate cancer: a cost-effectiveness analysis. Tumori. 2017 Jul 31;103(4):380–386.
   PubMed Web of Science ®Google Scholar
• Schultz NM, O’Day K, Sugarman R, et al. Budget Impact of Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer. J Manag Care Spec Pharm. 2020 Apr;26(4):538–549.
   PubMed Web of Science ®Google Scholar
• Aguiar PN Jr., Barreto CMN, Gutierres BS, et al. Cost effectiveness of chemohormonal therapy in patients with metastatic hormone-sensitive and non-metastatic high-risk prostate cancer. Einstein. 2017;15(3):349–354. Jul-Sep. .
   PubMed Web of Science ®Google Scholar
• Shah A, Shah R, Kebede N, et al. Real-world incidence and burden of adverse events among non-metastatic prostate cancer patients treated with secondary hormonal therapies following androgen deprivation therapy. J Med Econ. 2020 Apr;23(4):330–346.
   PubMed Web of Science ®Google Scholar
• Wu B, Li SS, Song J, et al. Total cost of care for castration-resistant prostate cancer in a commercially insured population and a medicare supplemental insured population. J Med Econ. 2020 Jan;23(1):54–63.
   PubMed Web of Science ®Google Scholar
• Armstrong A, Bui C, Fitch K, et al. Docetaxel chemotherapy in metastatic castration-resistant prostate cancer: cost of care in Medicare and commercial populations. Curr Med Res Opin. 2017 Jun;33(6):1133–1139. .
   PubMed Web of Science ®Google Scholar
• Mahlich J, Tsubota A, Imanaka K, et al. Burden of illness of chemotherapy in castration-resistant prostate cancer patients in Japan: a retrospective database analysis. Curr Med Res Opin. 2018 Oct;34(10):1855–1860.
   PubMed Web of Science ®Google Scholar
• Dragomir A, Dinea D, Vanhuyse M, et al. Drug costs in the management of metastatic castration-resistant prostate cancer in Canada. BMC Health Serv Res. 2014 Jun 13;14(1):252.
   PubMed Web of Science ®Google Scholar
• Restelli U, Ceresoli GL, Croce D, et al. Economic burden of the management of metastatic castrate-resistant prostate cancer in Italy: a cost of illness study. Cancer Manag Res. 2017;9:789–800.
   PubMed Web of Science ®Google Scholar
• Kreis K, Horenkamp-Sonntag D, Schneider U, et al. Treatment-Related Healthcare Costs of Metastatic Castration-Resistant Prostate Cancer in Germany: a Claims Data Study. Pharmacoeconomics Open. 2020; May 30. doi: https://doi.org/10.1007/s41669-020-00219-6.
   Google Scholar
• Ellis LA, Lafeuille M-H, Gozalo L, et al. Treatment Sequences and Pharmacy Costs of 2 New Therapies for Metastatic Castration-Resistant Prostate Cancer. Am Health Drug Benefits. 2015;8(4):185–195.
   PubMed Web of Science ®Google Scholar
• Schultz NM, Flanders SC, Wilson S, et al. Treatment Duration, Healthcare Resource Utilization, and Costs Among Chemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate: a Retrospective Claims Analysis. Adv Ther. 2018 Oct;35(10):1639–1655. .
   PubMed Web of Science ®Google Scholar
• Ramaswamy K, Lechpammer S, Mardekian J, et al. Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone. Adv Ther. 2020 May;37(5):2083–2097. .
   PubMed Web of Science ®Google Scholar
• Bui CN, Wang L, Baser O. Resource utilization and use of life-extending therapies and corticosteroids in prostate cancer patients with corticosteroid-sensitive comorbidities. Curr Med Res Opin. 2014 Nov;30(11):2355–2364.
   PubMed Web of Science ®Google Scholar
• Bui CN, O’Day K, Flanders S, et al. Budget Impact of Enzalutamide for Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. J Manag Care Spec Pharm. 2016 Feb;22(2):163–170. .
   PubMed Web of Science ®Google Scholar
• Pilon D, Queener M, Lefebvre P, et al. Cost per median overall survival month associated with abiraterone acetate and enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer. J Med Econ. 2016 Aug;19(8):777–784.
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010 Jul 29;363(5):411–422. .
   PubMed Web of Science ®Google Scholar
• Guirgis HM. The value of anticancer drugs in metastatic castrate-resistant prostate cancer: economic tools for the community oncologist. J Community Supportive Oncology. 2015 Oct;13(10):362–366.
   Google Scholar
• Pollard ME, Moskowitz AJ, Diefenbach MA, et al. Cost-effectiveness analysis of treatments for metastatic castration resistant prostate cancer. Asian J Urol. 2017 Jan;4(1):37–43.
   PubMed Web of Science ®Google Scholar
• Gong CL, Hay JW. Cost-effectiveness analysis of abiraterone and sipuleucel-T in asymptomatic metastatic castration-resistant prostate cancer. J Natl Compr Canc Netw. 2014 Oct;12(10):1417–1425.
   PubMed Web of Science ®Google Scholar
• Tirado Mercier E, Callejo Velasco D, Rubio Cabezas M, et al. Cost-effectiveness Analysis of Radium-223 Dichloride in Metastatic Castration-Resistant Prostate Cancer Patients Without Previous Chemotherapy Treatment in Spain. J Health Econ Outcomes Res. 2018;6(1):1–14.
   PubMedGoogle Scholar
• Andronis L, Goranitis I, Pirrie S, et al. Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747). BJU Int. 2017 Apr;119(4):522–529. .
   PubMed Web of Science ®Google Scholar
• Snedecor SJ, Carter JA, Kaura S, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectiveness analysis. J Med Econ. 2013;16(1):19–29.
   PubMedGoogle Scholar
• Stopeck A, Brufsky A, Kennedy L, et al. Cost-effectiveness of denosumab for the prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. J Med Econ. 2020 Jan;23(1):37–47.
   PubMed Web of Science ®Google Scholar
• Cristino J, Finek J, Jandova P, et al. Cost-effectiveness of denosumab versus zoledronic acid for preventing skeletal-related events in the Czech Republic. J Med Econ. 2017 Aug;20(8):799–812. .
   PubMed Web of Science ®Google Scholar
• Wilson L, Tang J, Zhong L, et al. New therapeutic options in metastatic castration-resistant prostate cancer: can cost-effectiveness analysis help in treatment decisions? J Oncology Pharmacy Practice: Official Publication of the International Society of Oncology Pharmacy Practitioners. 2014 Dec;20(6):417–425. .
   PubMed Web of Science ®Google Scholar
• Zhong L, Pon V, Srinivas S, et al. Therapeutic options in docetaxel-refractory metastatic castration-resistant prostate cancer: a cost-effectiveness analysis. PloS One. 2013;8(5):e64275. .
   PubMed Web of Science ®Google Scholar
• Massoudi M, Balk M, Yang H, et al. Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer. J Med Econ. 2017 Feb;20(2):121–128. .
   PubMed Web of Science ®Google Scholar
• Flannery K, Drea E, Hudspeth L, et al. Budgetary Impact of Cabazitaxel Use After Docetaxel Treatment for Metastatic Castration-Resistant Prostate Cancer. J Manag Care Spec Pharm. 2017 Apr;23(4):416–426. .
   PubMedGoogle Scholar
• Sorensen S, Ellis L, Wu Y, et al. Budgetary impact on a U.S. health plan adopting abiraterone acetate plus prednisone for the treatment of patients with metastatic castration-resistant prostate cancer. J Managed Care Pharmacy: JMCP. 2013;19(9):799–808. Nov-Dec. .
   PubMed Web of Science ®Google Scholar
• Koninckx M, Marco JL, Pérez I, et al. Effectiveness, safety and cost of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world data analysis. Clin Transl Oncol. 2019 Mar;21(3):314–323.
   PubMed Web of Science ®Google Scholar
• Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014 Sep 11;371(11):1028–1038.
   PubMed Web of Science ®Google Scholar
• Antonarakis ES, Lu C, Luber B, et al. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. JAMA Oncol. 2015;1(5):582–591. .
   PubMed Web of Science ®Google Scholar
• Markowski MC, Frick KD, Eshleman JR, et al. Cost-Savings Analysis of AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer Eligible for Treatment With Abiraterone or Enzalutamide. Prostate. 2016 Dec;76(16):1484–1490.
   PubMed Web of Science ®Google Scholar
• Pacheco-Orozco RA, Montealegre-Páez L. AR-V7 as a Biomarker for Resistance to Treatment with Abiraterone/Enzalutamide in Three Latin American Countries: a Hypothetical Cost-Saving Analysis. Oncologist. 2020 Dec;25(12):e1990-e1995.
   PubMed Web of Science ®Google Scholar
• Leongamornlert D, Mahmud N, Tymrakiewicz M, et al. Germline BRCA1 mutations increase prostate cancer risk. Br J Cancer. 2012;106(10):1697–1701. .
   PubMed Web of Science ®Google Scholar
• Kote-Jarai Z, Leongamornlert D, Saunders E, et al. BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. Br J Cancer. 2011;105(8):1230–1234. .
   PubMed Web of Science ®Google Scholar
• Sun L, Brentnall A, Patel S, et al. A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer. JAMA Oncol. 2019 Oct 3;5(12):1718–1730.
   PubMed Web of Science ®Google Scholar
• Krahn MD, Bremner KE, Luo J, et al. Long-term health care costs for prostate cancer patients on androgen deprivation therapy. Current Oncol. 2016 Oct;23(5):e443–e453.
   PubMed Web of Science ®Google Scholar
• Krahn MD, Bremner KE, Luo J, et al. Health care costs for prostate cancer patients receiving androgen deprivation therapy: treatment and adverse events. Current Oncol. 2014;21(3):e457–e465.
   PubMed Web of Science ®Google Scholar
• Goto R, Uda A, Hiroi S, et al. Cost analysis of leuprorelin acetate in Japanese prostate cancer patients: comparison between 6-month and 3-month depot formulations. J Med Econ. 2017 Nov;20(11):1155–1162.
   PubMed Web of Science ®Google Scholar
• Merseburger AS, Björk T, Whitehouse J, et al. Treatment costs for advanced prostate cancer using luteinizing hormone-releasing hormone agonists: a solid biodegradable leuprorelin implant versus other formulations. J Comp Eff Res. 2015 Sep;4(5):447–453.
   PubMed Web of Science ®Google Scholar
• Hatoum HT, Crawford ED, Nielsen SK, et al. Cost-effectiveness analysis comparing degarelix with leuprolide in hormonal therapy for patients with locally advanced prostate cancer. Expert Rev Pharmacoecon Outcomes Res. 2013 Apr;13(2):261–270.
   PubMed Web of Science ®Google Scholar
• Boyd KA, Jones RJ, Paul J, et al. Decision analytic cost-effectiveness model to compare prostate cryotherapy to androgen deprivation therapy for treatment of radiation recurrent prostate cancer. BMJ Open. 2015;5(10):e007925.
   PubMed Web of Science ®Google Scholar
• Nguyen C, Lairson DR, Swartz MD, et al. Cost-Effectiveness of Adding Androgen Deprivation Therapy to Radiation Therapy for Men with Advanced Prostate Cancer from a U.S. Payer’s Perspective. J Manag Care Spec Pharm. 2019 Feb;25(2):225–234.
   PubMed Web of Science ®Google Scholar
• Moussa M, Papatsoris A, Abou Chakra M, et al. Pharmacotherapeutic strategies for castrate-resistant prostate cancer. Expert Opin Pharmacother. 2020 Aug;21(12):1431–1448. .
   PubMed Web of Science ®Google Scholar
• Gravis G, Fizazi K, Joly F, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013 Feb;14(2):149–158. .
   PubMed Web of Science ®Google Scholar